
Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Italian Enthera Pharma raise €35m in Series A extension
Roche Venture Fund joined seed investor Sofinnova Partners and AbbVie Ventures and co-investors including the JDRF T1D Fund, an investor group...

German antibodies in demand in USA
Initially, Seattle-based Just - Evotec Biologics will receive US$28.6m from the Defense Health Agency ("DHA") under a partnership announced...

Janssen presents one-shot COVID-19 vaccine data
Janssen Pharmaceuticals’ Phase III adenoviral vector vaccine JNJ-78436735 gave immune protection over two and a half months after a single vaccine...

Two companies aim for 2nd-gen COVID vaccines
As scientific papers provide hints that mutants of SARS-CoV-2 that carry the N501Y and E484K mutations are able to reproduce more rapidly as the...

Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...

Rentschler Biopharma to produce 100m doses of CureVac vaccine
Rentschler Biopharma SE is preparing large scale cGMP production and formulation of Curevac’s mRNA vaccine CVnCoV. Under a contract, signed in...